Michael Frisby and Robert Eriksson of Stevens & Bolton predict that, with the record fines being imposed in the pharmaceutical industry for competition law breaches, life science companies could soon become targets of claimant law firms and litigation funders pursuing group claims.
Michael Frisby of Stevens & Bolton warns pharma companies that they may soon find themselves the target of a group action given the regulatory attention focused on the pharma sector and the appetite amongst litigation funders to invest in group actions, and cites recent examples where claims alleging breaches of competition law or high profile consumer claims were brought.
We’ll alert you to key situations and stories you should be aware of.
We deliver the important litigation finance news and analysis straight to your inbox each Monday morning.
The newsletter is always free.
